Patient
SITE003-0013
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2025-08-31
Adverse events
3
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 3
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-04 (study day 296); relationship: not assessed; serious criteria: hospitalization
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 295); relationship: not assessed
Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-06-13 (study day 91); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.